Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) treated with omalizumab, dupilumab or mepolizumab: review of the current knowledge towards an attempt to compare agents ’ efficacy – A systematic review

ConclusionsAlthough the present analysis showed a moderate supremacy of dupilumab, there is still no evidence-based answer to the question “which biologic agent is the most effective in CRS treatment?” Improved statistical methodology, head-to-head trials and real-life studies could lead to more robust conclusions, establishing the real role of the specific biologic agents.This article is protected by copyright. All rights reserved

Source: International Forum of Allergy and Rhinology - July 3, 2023 Category: Allergy & Immunology Authors: Georgios X. Papacharalampous, Jannis Constantinidis, George Fotiadis, Nan Zhang, Claus Bachert, Michael Katotomichelakis Tags: REVIEW ARTICLE Source Type: research